$MTVA
MetaVia Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024012272 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.742M $2.010M
YoY Change 8.88% 39.39%
% of Gross Profit
Research & Development $4.517M $8.074M
YoY Change 97.08% 241.54%
% of Gross Profit
Depreciation & Amortization $5.000K $6.000K
YoY Change
% of Gross Profit
Operating Expenses $4.517M $8.074M
YoY Change 97.08% 241.54%
Operating Profit -$6.259M -$10.08M
YoY Change 60.78% 164.95%
Interest Expense $310.0K $164.0K
YoY Change 93.75%
% of Operating Profit
Other Income/Expense, Net $607.0K $31.00K
YoY Change -774.44% -98.99%
Pretax Income -$5.652M -$10.05M
YoY Change 48.04% 1269.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.652M -$10.05M
YoY Change 48.74% 1336.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$1.85
Diluted Earnings Per Share -$0.55 -$1.85
COMMON SHARES
Basic Shares Outstanding 8.459M 4.906M
Diluted Shares Outstanding 10.21M 5.429M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.67M $27.93M
YoY Change -16.14% -2.63%
Cash & Equivalents $21.70M $27.93M
Short-Term Investments
Other Short-Term Assets $266.0K $583.0K
YoY Change -14.19% 19.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.94M $28.52M
YoY Change -16.1% -2.25%
LONG-TERM ASSETS
Property, Plant & Equipment $39.00K $44.00K
YoY Change -4.88% 780.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.00K
YoY Change 0.0%
Total Long-Term Assets $211.0K $234.0K
YoY Change -24.64% 4580.0%
TOTAL ASSETS
Total Short-Term Assets $21.94M $28.52M
Total Long-Term Assets $211.0K $234.0K
Total Assets $22.15M $28.75M
YoY Change -16.19% -1.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.017M $2.632M
YoY Change -48.66% 172.18%
Accrued Expenses $4.083M $2.601M
YoY Change 152.97% 27.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.114M $9.711M
YoY Change 93.01% 143.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $79.00K $98.00K
YoY Change -47.33%
Total Long-Term Liabilities $79.00K $98.00K
YoY Change -47.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.114M $9.711M
Total Long-Term Liabilities $79.00K $98.00K
Total Liabilities $9.193M $9.809M
YoY Change 88.57% 146.27%
SHAREHOLDERS EQUITY
Retained Earnings -$130.7M -$125.0M
YoY Change 26.89% 26.17%
Common Stock $9.000K $8.000K
YoY Change -76.32% -78.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.95M $18.94M
YoY Change
Total Liabilities & Shareholders Equity $22.15M $28.75M
YoY Change -16.19% -1.47%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$5.652M -$10.05M
YoY Change 48.74% 1336.14%
Depreciation, Depletion And Amortization $5.000K $6.000K
YoY Change
Cash From Operating Activities -$5.589M -$7.251M
YoY Change 98.19% 254.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $3.000K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$3.000K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -676.0K 19.20M
YoY Change -24100.0%
NET CHANGE
Cash From Operating Activities -5.589M -7.251M
Cash From Investing Activities 0.000 -3.000K
Cash From Financing Activities -676.0K 19.20M
Net Change In Cash -6.265M 11.95M
YoY Change 119.06% -662.16%
FREE CASH FLOW
Cash From Operating Activities -$5.589M -$7.251M
Capital Expenditures $0.00 $3.000K
Free Cash Flow -$5.589M -$7.254M
YoY Change 95.42% 254.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5059003
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5059003
CY2024Q2 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001638287
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8221000
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4906000
CY2024Q2 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q2 us-gaap Other Liability Current Related Party Counterparty Name Extensible Enumeration
OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration
http://www.gemphire.com/20240630#DongStMember
CY2023Q4 us-gaap Other Liability Current Related Party Counterparty Name Extensible Enumeration
OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration
http://www.gemphire.com/20240630#DongStMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37809
dei Entity Registrant Name
EntityRegistrantName
NeuroBo Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2389984
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Concord Avenue, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02138
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
702-9600
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
NRBO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8459196
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27934000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22435000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
583000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
77000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
28517000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22512000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
169000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
202000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2024Q2 us-gaap Assets
Assets
28751000
CY2023Q4 us-gaap Assets
Assets
22781000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2632000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
821000
CY2024Q2 nrbo Accrued Liabilities Clinical Trial Current
AccruedLiabilitiesClinicalTrialCurrent
2066000
CY2023Q4 nrbo Accrued Liabilities Clinical Trial Current
AccruedLiabilitiesClinicalTrialCurrent
3033000
CY2024Q2 nrbo Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
463000
CY2023Q4 nrbo Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
592000
CY2024Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
861000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
658000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3617000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
789000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
72000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9711000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5960000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
136000
CY2024Q2 us-gaap Liabilities
Liabilities
9809000
CY2023Q4 us-gaap Liabilities
Liabilities
6096000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8221000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4906000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
143966000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124945000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125032000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108265000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
18942000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16685000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28751000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22781000
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8074000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2364000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12978000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3001000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2010000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1442000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3987000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3325000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
10084000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
3806000
us-gaap Costs And Expenses
CostsAndExpenses
16965000
us-gaap Costs And Expenses
CostsAndExpenses
6326000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10084000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3806000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16965000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6326000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
133000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3072000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
203000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2988000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
164000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
401000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3072000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
198000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2988000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10053000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-734000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16767000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3338000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10053000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10053000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-734000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-734000
us-gaap Net Income Loss
NetIncomeLoss
-16767000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16767000
us-gaap Net Income Loss
NetIncomeLoss
-3338000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3338000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5428906
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5059003
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5259939
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5059003
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21750000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1436000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2604000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
20508000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5398000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-734000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
25196000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16685000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6714000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10076000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
134000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10053000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
18942000
us-gaap Net Income Loss
NetIncomeLoss
-16767000
us-gaap Net Income Loss
NetIncomeLoss
-3338000
us-gaap Share Based Compensation
ShareBasedCompensation
239000
us-gaap Share Based Compensation
ShareBasedCompensation
-50000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1000
us-gaap Depreciation
Depreciation
10000
us-gaap Depreciation
Depreciation
1000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
203000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2988000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
507000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
318000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1396000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
260000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1732000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1841000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13693000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4592000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
19998000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
798000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
80000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-80000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5499000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4676000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22435000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33364000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27934000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28688000
nrbo Deferred Issuance Costs Incurred But Not Yet Paid
DeferredIssuanceCostsIncurredButNotYetPaid
415000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6833000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">R</b><b style="font-weight:bold;">eclassification of prior year presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. Adjustments have been made to the condensed consolidated balance sheets to reclassify the presentation of certain current liabilities related to clinical trial accrued liabilities of $3.0 million and related party payable of $0.8 million from accrued expenses and other current liabilities. These reclassifications had no effect on the reported total current liabilities in the condensed consolidated balance sheets.</p>
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
313000
CY2024Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
111000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
39000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
159000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
38000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
583000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
77000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
88000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
44000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
403000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
118000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
45000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
166000
CY2024Q2 nrbo Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
463000
CY2023Q4 nrbo Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
592000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
658000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
203000
CY2024Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
861000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3600000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
800000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14834963
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
203914
nrbo Class Of Warrant Or Right Securities Called By Each Warrant Or Right Number Of Warrants Exchanged
ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged
8
CY2024Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P2Y
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
135000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
239000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-50000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
385921
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4700
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
398.30
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4577
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
391.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
59
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
689.72
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4700
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
398.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4636
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
394.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3125
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.829
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0354
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
141361
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.55
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
523000
CY2023Q4 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
5469
CY2023Q4 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
4.02
CY2023Q4 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested Balance
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedBalance
20000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
83899
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.41
nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriod
1563
nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue
4.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
7147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
29000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
218113
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.90
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1056000
CY2024Q2 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
7032
CY2024Q2 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
4.04
CY2024Q2 nrbo Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested Balance
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedBalance
34000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10053000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-734000
us-gaap Net Income Loss
NetIncomeLoss
-16767000
us-gaap Net Income Loss
NetIncomeLoss
-3338000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5428906
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5059003
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5259939
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5059003
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5428906
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5059003
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5259939
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5059003
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-012272-index-headers.html Edgar Link pending
0001558370-24-012272-index.html Edgar Link pending
0001558370-24-012272.txt Edgar Link pending
0001558370-24-012272-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrbo-20240630.xsd Edgar Link pending
nrbo-20240630x10q.htm Edgar Link pending
nrbo-20240630x10q001.jpg Edgar Link pending
nrbo-20240630xex31d1.htm Edgar Link pending
nrbo-20240630xex31d2.htm Edgar Link pending
nrbo-20240630xex32d1.htm Edgar Link pending
nrbo-20240630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
nrbo-20240630_cal.xml Edgar Link unprocessable
nrbo-20240630_def.xml Edgar Link unprocessable
nrbo-20240630_lab.xml Edgar Link unprocessable
nrbo-20240630_pre.xml Edgar Link unprocessable
nrbo-20240630x10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable